(Q38181019)

30 August 2017

title

Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation (English)

1 reference

30 August 2017

0 references

0 references

0 references

2

Gillian M Keating

1 reference

30 August 2017

Celeste B Burness

1

1 reference

30 August 2017

publication date

1 March 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

74

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

353-375

1 reference

Oxycodone: a review of its use in the management of pain

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Opioid-induced bowel dysfunction: pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Opioids in chronic non-cancer pain: systematic review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Validated in vitro/in vivo correlation of prolonged-release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Oxycodone: a pharmacological and clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Opioid receptors in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Oral naloxone reverses opioid-associated constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Costs associated with treatment of chronic low back pain: an analysis of the UK General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Constipation in advanced cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

High doses of oxycodone-naloxone combination may provide poor analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

The impact of medication regimen factors on adherence to chronic treatment: a review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Reducing the "pill burden".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Dependence and addiction during chronic opioid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0177-9

Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice

21 January 2018

1 reference

12 December 2020

A review of abuse-deterrent opioids for chronic nonmalignant pain.

1 reference

12 December 2020

Oxycodone. Pharmacological profile and clinical data in chronic pain management.

1 reference

12 December 2020

American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance.

1 reference

12 December 2020

Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy.

1 reference

12 December 2020

The pharmacokinetics of oxycodone

1 reference

12 December 2020

Low absolute bioavailability of oral naloxone in healthy subjects.

1 reference

12 December 2020

Management of cancer pain: ESMO Clinical Practice Guidelines

1 reference

12 December 2020

Health care costs, work productivity and activity impairment in non-malignant chronic pain patients

1 reference

12 December 2020

The place of oxycodone/naloxone in chronic pain management

1 reference

12 December 2020

Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial

1 reference

12 December 2020

Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers

1 reference

12 December 2020

10.1007/S40265-014-0177-9

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1035582834

0 references

1 reference